Blog
Addressing the Suboptimal Pneumococcal Vaccination Coverage in Belgium: Key Insights and Recommendations
Nov 10, 2025

The Scope of the Problem: Suboptimal Vaccination Rates

The white paper, funded by Pfizer Belgium and developed by IQVIA Belux, reveals startling insights into pneumococcal vaccination coverage in Belgium. Based on an analysis of pharmacy dispensing data over an 11-year period, the study found that only 13% of at-risk individuals are vaccinated. This suboptimal rate leaves a significant proportion of high-risk populations vulnerable to severe complications of pneumococcal disease, such as sepsis, meningitis, and pneumonia.

Key findings from the research include:

  • Highest vaccination rates (21%) were observed among immunocompromised patients.
  • Patients with two or more comorbidities, such as chronic heart disease and diabetes, had a vaccination rate of 17%.
  • Vaccination rates were lowest for patients with "other comorbidities" (7%), such as chronic liver, kidney, or neurological conditions.
  • A geographical disparity was identified, with systematically lower vaccination rates in the southern region of Belgium.

Why This Matters: Preventable Burden on Healthcare

The findings underscore the urgency of addressing vaccination gaps. In 2024, Belgium recorded an all-time high of 2,120 cases of Invasive Pneumococcal Disease (IPD)—over 70% of which were caused by serotypes covered by available vaccines. Pneumococcal disease is not only life-threatening but also places a significant burden on healthcare systems. For instance, it accounts for approximately 6,000 hospitalizations and 450 deaths annually in Belgium, predominantly affecting the elderly and individuals with comorbidities.

Given the preventability of most IPD cases through vaccination, these statistics highlight a missed opportunity to safeguard public health and reduce healthcare costs.

For more detailed insights and tailored recommendations, you are encouraged to read the full white paper or contact Kristin Van Den Daele for additional information.

Contact Us